Tenaya Therapeutics, Inc. (TNYA) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $22.00K; Additional Paid in CapitalUSD $737.06M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD $-667.67M.
- 2026-03-31: Common Stock, Value, IssuedUSD $21.00K; Additional Paid in CapitalUSD $730.45M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD $-624.28M.
- 2025-12-31: Common Stock, Value, IssuedUSD $21.00K; Additional Paid in CapitalUSD $728.25M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $0.00; Retained Earnings (Accumulated Deficit)USD $-605.01M.
- 2025-09-30: Common Stock, Value, IssuedUSD $16.00K; Additional Paid in CapitalUSD $667.68M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD $-584.83M.
Tenaya Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $22.00K | $737.06M | (m) | $-667.67M | $69.41M | 3 month · $1.70M |
| 2026-03-31 | $21.00K | $730.45M | (m) | $-624.28M | $106.19M | 3 month · $2.20M |
| 2025-12-31 | $21.00K | $728.25M | $0.00 | $-605.01M | $123.27M | 12 month · $13.05M |
| 2025-09-30 | $16.00K | $667.68M | (m) | $-584.83M | $82.87M | 3 month · $2.93M |
| 2025-06-30 | $16.00K | $664.37M | $-1.00K | $-564.56M | $99.83M | 3 month · $3.64M |
| 2025-03-31 | $16.00K | $660.66M | $-10.00K | $-541.27M | $119.40M | 3 month · $3.73M |
| 2024-12-31 | $8.00K | $607.23M | $28.00K | $-514.41M | $92.85M | 12 month · $16.50M |
| 2024-09-30 | $8.00K | $603.09M | $76.00K | $-490.57M | $112.60M | 3 month · $3.91M |
| 2024-06-30 | $8.00K | $599.00M | $-67.00K | $-464.94M | $134.00M | 3 month · $4.61M |
| 2024-03-31 | $8.00K | $593.80M | $-120.00K | $-435.51M | $158.18M | 3 month · $4.22M |
| 2023-12-31 | $7.00K | $542.80M | $-106.00K | $-403.28M | $139.42M | 12 month · $15.31M |
| 2023-09-30 | $7.00K | $538.49M | $-261.00K | $-373.35M | $164.88M | 3 month · $4.01M |
| 2023-06-30 | $7.00K | $534.47M | $-333.00K | $-344.20M | $189.94M | 3 month · $3.83M |
| 2023-03-31 | $7.00K | $526.46M | $-120.00K | $-310.94M | $215.41M | 3 month · $3.51M |
| 2022-12-31 | $7.00K | $522.95M | $-378.00K | $-279.20M | $243.38M | 12 month · $11.47M |
| 2022-09-30 | $4.00K | $442.77M | $-767.00K | $-245.68M | $196.33M | 3 month · $3.17M |
| 2022-06-30 | $4.00K | $439.59M | $-739.00K | $-214.99M | $223.87M | 3 month · $3.01M |
| 2022-03-31 | $4.00K | $436.31M | $-631.00K | $-186.59M | $249.10M | 3 month · $2.09M |
| 2021-12-31 | $4.00K | $434.20M | $-141.00K | $-155.53M | $278.53M | 12 month · $2.95M |
| 2021-09-30 | $4.00K | $433.11M | $-23.00K | $-129.38M | $303.70M | 3 month · $968.00K |
| 2021-06-30 | (m) | $2.60M | (m) | $-111.12M | $-108.54M | 3 month · $502.00K |
| 2021-03-31 | (m) | (m) | (m) | (m) | $-93.94M | 3 month · $432.00K |
| 2020-12-31 | (m) | $1.58M | (m) | $-82.81M | $-81.31M | 12 month · $741.00K |
| 2020-09-30 | (m) | (m) | (m) | (m) | $-71.23M | 3 month · $198.00K |
| 2020-06-30 | (m) | (m) | (m) | (m) | $-61.15M | 3 month · $185.00K |
| 2020-03-31 | (m) | (m) | (m) | (m) | $-52.62M | 3 month · $154.00K |
| 2019-12-31 | (m) | (m) | (m) | (m) | $-43.74M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |